The Motley Fool
20 Jul 2026, 00:48 UTC · 21h ago
Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
20 Jul 2026, 00:48 UTC · 21h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA approved Afrezza for use by children aged six and older living with diabetes in May. — Expanding the addressable patient population for a core product typically drives revenue growth and increases the company's valuation.
+0.60MannKind's inhaled insulin product, Afrezza, saw year-over-year sales growth of 115% in the first quarter of 2026. — Strong triple-digit growth in a lead product demonstrates market adoption and positive commercial momentum.
+0.50CEO Michael Castagna sold 363,200 shares of common stock on July 15, 2026. — Insider selling can be seen as a bearish signal, though the article mitigates this by attributing it to tax obligations from RSU vesting.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company reported 115% year-over-year growth for Afrezza and received FDA approval for use in children.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
15m ago
